Sensus Healthcare (NASDAQ:SRTS) Stock Passes Above Fifty Day Moving Average – Here’s What Happened

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $2.92 and traded as high as $2.98. Sensus Healthcare shares last traded at $2.98, with a volume of 10,982 shares traded.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on SRTS shares. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Friday, July 17th. Citigroup reaffirmed a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Sensus Healthcare presently has an average rating of “Moderate Buy” and an average target price of $7.17.

Sensus Healthcare Stock Up 3.0%

The firm has a market cap of $50.53 million, a PE ratio of -6.53 and a beta of 1.10. The stock’s fifty day simple moving average is $2.92 and its two-hundred day simple moving average is $3.72.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The business had revenue of $3.39 million for the quarter, compared to the consensus estimate of $5.32 million.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in Sensus Healthcare in the second quarter worth $252,000. Bank of New York Mellon Corp bought a new position in shares of Sensus Healthcare during the second quarter valued at $303,000. North Star Investment Management Corp. purchased a new position in shares of Sensus Healthcare in the 1st quarter worth about $500,000. XTX Topco Ltd purchased a new position in shares of Sensus Healthcare in the 4th quarter worth about $77,000. Finally, Rothschild Wealth LLC bought a new position in Sensus Healthcare in the 4th quarter worth about $500,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.